Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Singulex

1701 Harbor Bay Parkway Suite 200
Alameda, CA 94502
USA
510.814.9000
Website Company Summary Management Team
Management

CEO: Guido Baechler (5/23/2013)
President/COO/Operations: Mark Stene
General Management: Karen Richards ; Lynn R. Zieske (1/31/2009) ; Thomas Schlumpberger (2/28/2015) ; Patricia Ryan (2014); Peter Heseltine (5/21/2014)
Finance: Gary S. Tom (7/31/2010) ; Eric J. Hall (2016)
Technology: Jeffrey Bishop (9/30/2013) ; John A. Todd (2006)
Business Development: Linda M. Greub
Board

Outside board: (May no longer be on the board) R. Douglas Norby (Xperi Former CFO) Philippe J. Goix (Singulex Former President/CEO) Andre Marion (Life Technologies Founder) Hironori Hozoji (JAFCO Life Science Investment Former investment officer) Heiner Dreismann (Roche Molecular Diagnostics CEO) Carl L. Gordon (OrbiMed General Partner) Stephen L. Rose (Fisk Ventures Managing Director) Gregory R. Johnson (Prolog Ventures) Fred K. Vogt (FKV Enterprises)
Former outside board: Mickey S. Urdea (Tethys Bioscience) Jeff Halvin (Johnson Keland Management)
Company

Business description: Singulex is the developer and leading provider of single molecule counting (SMCTM) technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management, and fueling the discovery and development of new therapeutics. Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex currently is developing the Sgx ClarityTM System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide.
Customers include: Washington University
Partners include: Novartis Pharma ;  The Dutch Technology Foundation ;  Wyeth Pharmaceuticals
Capital

Rounds: 7
Recent Fundings: May 2016   Sep 2013
Capital raised: 132.3M
Last Round: 50.0M
Ownership: Private   Ipo Filing
VCs include: Icon VenturesOrbiMed;  Fisk Venture ;  Prolog Ventures;  unnamed investor ;  Grifols
Corporate investors: GE Capital

Last Tweets


 

Last Mentions


Overview
Record updated: May 2016
Sector: Software
Rounds: 7
Recent Fundings: May 2016   Sep 2013
Capital Raised: 132.3M
Last Round: 50.0M
Ownership: Private   Ipo Filing